Biotech Startups

ARIZ Precision Medicine develops cancer treatments that combine biological and nanotechnology approaches to target the genetic and epigenetic drivers of cancer, aiming to kill cancer cells while leaving healthy cells undamaged. The company designs targeted drug delivery systems intended to concentrate drugs inside cancer cells.

3 investors

ArkeaBio develops a methane-reducing vaccine for cattle that lowers agricultural emissions without disrupting farm operations, targeting livestock producers to enable low-carbon dairy and beef production. The vaccine activates a natural immune response in ruminants and integrates seamlessly with existing farming practices.

3 investors

ArkVax develops glycoconjugate vaccines for animal health using genetic engineering of bacterial cells, aiming to provide broader protection than current vaccines. Its technology targets antibacterial and zoonotic diseases to help combat antimicrobial resistance in both livestock and humans.

3 investors

Aroa Biosurgery develops soft tissue repair and wound management products based on its AROA ECM extracellular matrix platform, including bioscaffolds for acute and chronic wounds, surgical reconstruction, and hernia repair. Its products, such as Endoform, Myriad Matrix, and Symphony, are used by surgeons and clinicians for soft tissue repair and reconstruction.

3 investors

Arum Therapeutics is a biotechnology company developing therapeutics, with a research-focused pipeline.

3 investors

Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.

3 investors

Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages. It provides expertise and collaboration to support the development and manufacturing of these therapies.

3 investors

Asieris (亚虹医药) is a pharmaceutical company developing diagnostic and therapeutic products focused on women's reproductive health and urologic cancers, including treatments for cervical precancerous lesions and bladder cancer. Its portfolio includes a non-invasive portable cervical photodynamic therapy product and a blue-light cystoscopy system for bladder cancer diagnosis, marketed in China.

3 investors

AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

3 investors

Aspect Analytics develops computational infrastructure for spatial biology analysis, enabling scientists to extract actionable insight from multimodal biological data to accelerate drug development. The company combines spatial omics, imaging analysis, and machine learning to help research teams understand tissue architecture and disease mechanisms.

3 investors

ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments. The company operates in the preclinical and clinical stage biotechnology space.

3 investors

Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients. The device is investigational and not yet available for sale.

3 investors

AtlasBase builds a hybrid Bio-Silicon platform that stores digital data in synthetic DNA and performs computation directly within the molecules, offering petabyte-scale archives with near-zero power and long-term durability. It targets enterprises needing massive data archiving and parallel molecular computation.

3 investors

Atomo Diagnostics develops diagnostic ecosystems and mobile applications for point-of-care testing, including whole-blood cassettes and reader devices compatible with smartphones for remote diagnostics. The company serves clinicians and self-test users in the in-vitro diagnostics and digital health markets.

3 investors

Atticus Pharma develops immunodermatology therapeutics using patented sustained-release technology for enhanced delivery to the viable epidermis. The company focuses on dermatological treatments leveraging its proprietary drug delivery platform.

3 investors

Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.

3 investors

Avammune is a biotech company developing novel therapeutic modalities to address hard-to-treat cancers with distinct mechanisms of action. The company focuses on patient-centric oncology drug discovery, emphasizing improved compliance, ease of administration, and greater accessibility.

3 investors

Avivomed is a medical device company developing minimally invasive neuromodulation therapies for patients with obstructive sleep apnea. Based in the Minneapolis area, it targets mild-to-moderate OSA patients who cannot tolerate CPAP.

3 investors

Aviwell develops microbiota-based feed solutions to improve animal health and growth for livestock and fish producers in the agri-food industry. It uses a hybrid AI/ML discovery platform combining in-silico and in-vivo approaches, drawing on research into the gut-brain microbiota axis, to create natural direct fed microbials.

3 investors

AXOL is a biotech company backed by investors including Par Equity, Meltwind Advisory, and Scottish Enterprise.

3 investors

b12 develops AI agents and lab automation software to help chemists plan, optimize, and execute the synthesis of complex molecules. The platform combines chemistry expertise with agentic AI systems to streamline organic synthesis workflows.

3 investors

Bain Capital Life Sciences is an investment firm that deploys capital into biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on enterprises addressing unmet medical needs. The team combines venture, private equity, and operating expertise to support clinical and commercial-stage companies through key phases of development and value creation.

3 investors

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.

3 investors

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).

3 investors